Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/CCE.0000000000000258 http://scihub22266oqcxt.onion/10.1097/CCE.0000000000000258 33134948!7566862!33134948     free     free     free       Crit+Care+Explor 2020 ; 2 (10): e0258 Nephropedia Template TP {{tp|p=33134948|t=2020. A Method to Improve Continuous Renal Replacement Therapy Circuit Survival Time in Critically Ill Coronavirus Disease 2019 Patients With Acute Kidney Injury |pdf=|usr=}}{{33134948}} gab.com Text A Method to Improve Continuous Renal Replacement Therapy Circuit Survival Time in Critically Ill Coronavirus Disease 2019 Patients With Acute Kidney Injury JO: Crit Care Explor http://www.kidney.de/pget.php?&tw=1&pmid=33134948 #FOAvip OBJECTIVES: Optimizing continuous renal replacement therapy circuit survival in coronavirus disease 2019 patients admitted to the ICU. DESIGN: Single-center prospective observational cohort study. SETTING: Tertiary academic teaching ICU. PATIENTS: Between March 19, 2020, and May 18, 2020, 11 out of 101 coronavirus disease 2019 patients were treated with continuous renal replacement therapy comprising 127 continuous renal replacement therapy days. INTERVENTIONS: A nonrandomized observational comparison of circuit anticoagulation modalities using standard regional citrate anticoagulation, continuous IV heparin anticoagulation, or the combination of regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin. MEASUREMENTS AND MAIN RESULTS: Circuit patency was shorter than 24 hours using standard regional citrate anticoagulation or continuous IV heparin anticoagulation. Median circuit survival increased with at least 165% when the combination of regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin was applied. CONCLUSIONS: Continuous renal replacement therapy circuit patency is diminished in coronavirus disease 2019 ICU patients. Combining regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin increases filter survival as compared with regional citrate anticoagulation alone in this nonrandomized observational study. Twit Text FOAVip A Method to Improve Continuous Renal Replacement Therapy Circuit Survival Time in Critically Ill Coronavirus Disease 2019 Patients With Acute Kidney Injury ????Crit Care Explor http://www.kidney.de/pget.php?&tw=1&pmid=33134948 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33134948 #FOAvip English Wikipedia <ref>{{Cite pmid|33134948}}</ref> A Method to Improve Continuous Renal Replacement Therapy Circuit Survival Time in Critically Ill Coronavirus Disease 2019 Patients With Acute Kidney Injury #MMPMID33134948 Volbeda M; Londema M; van Meurs M; Stegeman CA; Gansevoort RT; Berger SP; van der Voort PHJ; Franssen CFM Crit Care Explor 2020[Oct]; 2 (10): e0258 PMID33134948show ga OBJECTIVES: Optimizing continuous renal replacement therapy circuit survival in coronavirus disease 2019 patients admitted to the ICU. DESIGN: Single-center prospective observational cohort study. SETTING: Tertiary academic teaching ICU. PATIENTS: Between March 19, 2020, and May 18, 2020, 11 out of 101 coronavirus disease 2019 patients were treated with continuous renal replacement therapy comprising 127 continuous renal replacement therapy days. INTERVENTIONS: A nonrandomized observational comparison of circuit anticoagulation modalities using standard regional citrate anticoagulation, continuous IV heparin anticoagulation, or the combination of regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin. MEASUREMENTS AND MAIN RESULTS: Circuit patency was shorter than 24 hours using standard regional citrate anticoagulation or continuous IV heparin anticoagulation. Median circuit survival increased with at least 165% when the combination of regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin was applied. CONCLUSIONS: Continuous renal replacement therapy circuit patency is diminished in coronavirus disease 2019 ICU patients. Combining regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin increases filter survival as compared with regional citrate anticoagulation alone in this nonrandomized observational study. ?A Method to Improve Continuous Renal Replacement Therapy Circuit Survi(epmc).pdf DeepDyve Pubget Overpricing